Injection of Syfovre: Usage, Pricing, Potential Adverse Effects, and Further Details
In a significant development for the treatment of age-related macular degeneration (AMD), Syfovre, a branded injectable solution, has been approved by the Food and Drug Administration (FDA) for the treatment of geographic atrophy. As of August 2025, however, there are currently no publicly available records or reports indicating ongoing development or plans for a generic version of Syfovre.
Syfovre is administered as an injection into a specific area of the eye by an eye specialist at their clinic or office. It is a long-term treatment, and the usual dosage is one injection of 15 mg/0.1 mL into the affected eye, given once every 25 to 60 days.
Before receiving Syfovre, it is crucial to discuss your health history with your doctor, as the drug may not be suitable for individuals with certain medical conditions or factors affecting their health. Females who can become pregnant should use birth control during treatment and for at least 40 days after the last injection. Pregnant women and those planning a pregnancy should also consult their doctor before using Syfovre.
It is not known whether Syfovre should be used while breastfeeding. If you are breastfeeding or planning to do so, it is advisable to discuss this with your doctor before receiving this medication.
Syfovre is used for a certain type of AMD, and another drug, Izervay, has also been approved for this purpose. It is worth noting that Syfovre may be prescribed off-label for other eye-related conditions.
While there are no generic alternatives to Syfovre at present, it is essential to remember that missing a dose should be addressed promptly by contacting your eye specialist to reschedule.
As with any medication, Syfovre may cause side effects. Long-term side effects can potentially lead to vision loss, including an increased risk of wet age-related macular degeneration, detached retina, and endophthalmitis.
In conclusion, Syfovre is a valuable addition to the treatment options for age-related macular degeneration. However, as of August 2025, there are no publicly available records or reports indicating the development or plans for a generic version of Syfovre. It is recommended that individuals seeking the latest developments should monitor FDA biosimilar releases or specialized ophthalmology drug pipelines for future updates.
Read also:
- Symptoms of Thrombophlebitis Include: Pain, Inflammation, Redness, and Various Other Markers
- Chest Pain Caused by Compressed Nerves: A Possibility Explored
- Incidence and risk factors associated with cystic fibrosis: A statistical overview
- Hypothyroidism in Canines: A Comprehensive Look, Written by Catherine Barnette, DVM, and Reviewed by Emily Oliver, CVT on 07/31/2025. Published on 07/21/2023. Sharing options include Facebook, Twitter, Email, and Print.
